Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
Enorama Pharma AB (ERMA) - Total Liabilities
Latest total liabilities as of September 2025: Skr17.22 Million SEK
Based on the latest financial reports, Enorama Pharma AB (ERMA) has total liabilities worth Skr17.22 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enorama Pharma AB - Total Liabilities Trend (2014–2024)
This chart illustrates how Enorama Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enorama Pharma AB Competitors by Total Liabilities
The table below lists competitors of Enorama Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FINNING INTL (CIH.SG)
STU:CIH
|
Germany | €5.33 Billion |
|
Fuse Medical Inc
PINK:FZMD
|
USA | $19.55 Million |
|
Alkame Holdings Inc
PINK:ALKM
|
USA | $5.09 Million |
|
Clubhouse Media Group Inc
PINK:CMGR
|
USA | $10.01 Million |
|
Taurus Gold Corp.
PINK:TARGF
|
USA | $479.15K |
Liability Composition Analysis (2014–2024)
This chart breaks down Enorama Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enorama Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enorama Pharma AB (2014–2024)
The table below shows the annual total liabilities of Enorama Pharma AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr8.09 Million | -45.50% |
| 2023-12-31 | Skr14.85 Million | -13.67% |
| 2022-12-31 | Skr17.20 Million | -41.86% |
| 2021-12-31 | Skr29.58 Million | -24.40% |
| 2020-12-31 | Skr39.13 Million | +10.52% |
| 2019-12-31 | Skr35.40 Million | +62.33% |
| 2018-12-31 | Skr21.81 Million | +168.41% |
| 2017-12-31 | Skr8.13 Million | +78.73% |
| 2016-12-31 | Skr4.55 Million | +71.95% |
| 2015-12-31 | Skr2.64 Million | +155.71% |
| 2014-12-31 | Skr1.03 Million | -- |